Can Midostaurin be used in combination with chemotherapy?

Midostaurin is a multi-target tyrosine kinase inhibitor. Its most prominent feature is its ability to inhibit FLT3 mutations, which account for a relatively high proportion of patients with acute myeloid leukemia (AML) and are often associated with rapid disease progression and high relapse rates. In the past, the standard treatment plan for AML was mostly based on the "7+3" plan, that is, induction therapy with cytarabine combined with daunorubicin, followed by consolidation therapy with cytarabine.

However, this traditional regimen is not very effective for patients with positive FLT3 mutations Therefore, clinical trials have begun to explore combination strategies of targeted drugs and chemotherapy. Midostaurin has been approved overseas for use in combination with the standard chemotherapy regimen of cytarabine and daunorubicin for newly diagnosed FLT3 mutation-positive AML patients. During the specific treatment process, doctors will conduct genetic testing before treatment to confirm whether the patient carries the FLT3 mutation, and then consider using midostaurin in combination with chemotherapy.

The advantage of the combination regimen is that it works simultaneously through dual mechanisms: chemotherapy drugs kill rapidly proliferating leukemia cells, while midostaurin precisely inhibits theFLT3 signaling pathway, blocking the survival and spread of tumor cells, thereby achieving longer-term remission. It should be noted that the combination of midostaurin and chemotherapy may cause higher adverse reactions such as bone marrow suppression, nausea, vomiting, and oral mucositis. Therefore, patients need to strictly monitor blood changes during treatment and cooperate with doctors for supportive treatment.

In general, midostaurin can indeed be used in combination with chemotherapy, and has been recommended by multiple international guidelines as a first-line treatment option for FLT3 mutation-positive AML. For patients, the emergence of combination drugs not only improves the overall prognosis, but also marks the gradual transition of AML from the era of traditional chemotherapy to the stage of targeted combination precision medicine.

Reference materials:https://go.drugbank.com/drugs/DB06595